136 patents
Page 5 of 7
Utility
Modulation of Lnc05 expression
15 Jun 21
Provided herein are methods, compounds, and compositions for reducing expression of Inc05 in a cell or individual.
Allen Tingjin Yu, David L. Spector, Frank Rigo, Susan M. Freier, Jan Bergmann, Carmen Berasain
Filed: 1 Dec 17
Utility
Compounds and methods for reducing FXI expression
1 Jun 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject.
Huynh-Hoa Bui
Filed: 6 Nov 20
Utility
Allele specific modulators of P23H rhodopsin
25 May 21
The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject.
Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
Filed: 28 Aug 19
Utility
Modulators of PCSK9 expression
11 May 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
Filed: 1 Nov 19
Utility
Methods of modulating KEAP1
30 Mar 21
Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal.
Richard Lee, Jeffrey R. Crosby
Filed: 16 Mar 17
Utility
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
23 Mar 21
Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal.
Eric E. Swayze, Susan M. Freier
Filed: 23 Oct 18
Utility
Compositions and methods for modulating apolipoprotein C-III expression
23 Feb 21
Provided herein are oligomeric compounds with conjugate groups targeting apolipoprotein C-III (ApoCIII).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Filed: 7 Feb 18
Utility
Modulators of APOL1 expression
23 Feb 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
Susan M. Freier
Filed: 21 May 19
Utility
Compounds and methods for modulating angiotensinogen expression
9 Feb 21
Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof.
Adam Mullick, Mark J. Graham, Punit P. Seth, Susan M. Freier
Filed: 7 Oct 16
Utility
Methods for reducing LRRK2 expression
2 Feb 21
Provided herein are methods for decreasing LRRK2 mRNA expression.
Hien Thuy Zhao, Holly Kordasiewicz
Filed: 5 Jan 17
Utility
Compositions and methods for modulating apolipoprotein (a) expression
4 Jan 21
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)].
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Filed: 6 Feb 18
Utility
Compositions and methods for modulating angiopoietin-like 3 expression
28 Dec 20
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
Filed: 25 Feb 18
Utility
Oligomeric compounds comprising α-β-constrained nucleic acid
14 Dec 20
The present disclosure provides oligomeric compounds comprising at least one α-β-constrained nucleic acid as provided herein.
Michael Oestergaard, Eric E. Swayze, Punit P. Seth
Filed: 3 Jan 19
Utility
Modulators of DNM2 expression
14 Dec 20
The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
Susan M. Freier
Filed: 14 Jan 19
Utility
Methods for treating hypercholesterolemia
7 Dec 20
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C.
Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
Filed: 6 Aug 18
Utility
Modulation of SMN expression
30 Nov 20
Certain embodiments are directed to methods and compounds for inhibiting SMN-NAT, the natural antisense transcript of SMN.
Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
Filed: 10 Apr 16
Utility
Conjugated antisense compounds and their use
23 Nov 20
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 25 Dec 18
Utility
Modulation of huntingtin expression
16 Nov 20
Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal.
Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
Filed: 25 Feb 20
Utility
Compounds and methods for the modulation of proteins
2 Nov 20
In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell.
Stanley T. Crooke, Xue-hai Liang, Wen Shen
Filed: 15 Nov 15
Utility
Modulation of alpha synuclein expression
26 Oct 20
Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression.
Susan M. Freier
Filed: 17 Apr 17